Cargando…

Humoral and cellular response to the COVID-19 vaccine in immunocompromised children

BACKGROUND: A suboptimal response to the 2-dose COVID-19 vaccine series in the immunocompromised population prompted recommendations for a 3rd primary dose. We aimed to determine the humoral and cellular immune response to the 3rd COVID-19 vaccine in immunocompromised children. METHODS: Prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgans, Heather A., Bradley, Todd, Flebbe-Rehwaldt, Linda, Selvarangan, Rangaraj, Bagherian, Amber, Barnes, Aliessa P., Bass, Julie, Cooper, Ashley M., Fischer, Ryan, Kleiboeker, Steve, Lee, Brian R., LeMaster, Cas, Markus, Kelsey, Morrison, Stephen, Myers, Angela, Myers, Doug, Payne, Erin, Schuster, Jennifer E., Standley, Sarah, Wieser, Andrea, Warady, Bradley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662120/
https://www.ncbi.nlm.nih.gov/pubmed/36376507
http://dx.doi.org/10.1038/s41390-022-02374-4
_version_ 1784830624229490688
author Morgans, Heather A.
Bradley, Todd
Flebbe-Rehwaldt, Linda
Selvarangan, Rangaraj
Bagherian, Amber
Barnes, Aliessa P.
Bass, Julie
Cooper, Ashley M.
Fischer, Ryan
Kleiboeker, Steve
Lee, Brian R.
LeMaster, Cas
Markus, Kelsey
Morrison, Stephen
Myers, Angela
Myers, Doug
Payne, Erin
Schuster, Jennifer E.
Standley, Sarah
Wieser, Andrea
Warady, Bradley
author_facet Morgans, Heather A.
Bradley, Todd
Flebbe-Rehwaldt, Linda
Selvarangan, Rangaraj
Bagherian, Amber
Barnes, Aliessa P.
Bass, Julie
Cooper, Ashley M.
Fischer, Ryan
Kleiboeker, Steve
Lee, Brian R.
LeMaster, Cas
Markus, Kelsey
Morrison, Stephen
Myers, Angela
Myers, Doug
Payne, Erin
Schuster, Jennifer E.
Standley, Sarah
Wieser, Andrea
Warady, Bradley
author_sort Morgans, Heather A.
collection PubMed
description BACKGROUND: A suboptimal response to the 2-dose COVID-19 vaccine series in the immunocompromised population prompted recommendations for a 3rd primary dose. We aimed to determine the humoral and cellular immune response to the 3rd COVID-19 vaccine in immunocompromised children. METHODS: Prospective cohort study of immunocompromised participants, 5–21 years old, who received 2 prior doses of an mRNA COVID-19 vaccine. Humoral and CD4/CD8 T-cell responses were measured to SARS-CoV-2 spike antigens prior to receiving the 3rd vaccine dose and 3–4 weeks after the 3rd dose was given. RESULTS: Of the 37 participants, approximately half were solid organ transplant recipients. The majority (86.5%) had a detectable humoral response after the 2nd and 3rd vaccine doses, with a significant increase in antibody levels after the 3rd dose. Positive T-cell responses increased from being present in 86.5% to 100% of the cohort after the 3rd dose. CONCLUSIONS: Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This supports the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in this population. IMPACT: Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This is the first prospective cohort study to analyze both the humoral and T-cell immune response to the 3rd COVID-19 primary vaccine dose in children who are immunocompromised. The results of this study support the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in the immunosuppressed pediatric population.
format Online
Article
Text
id pubmed-9662120
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-96621202022-11-14 Humoral and cellular response to the COVID-19 vaccine in immunocompromised children Morgans, Heather A. Bradley, Todd Flebbe-Rehwaldt, Linda Selvarangan, Rangaraj Bagherian, Amber Barnes, Aliessa P. Bass, Julie Cooper, Ashley M. Fischer, Ryan Kleiboeker, Steve Lee, Brian R. LeMaster, Cas Markus, Kelsey Morrison, Stephen Myers, Angela Myers, Doug Payne, Erin Schuster, Jennifer E. Standley, Sarah Wieser, Andrea Warady, Bradley Pediatr Res Clinical Research Article BACKGROUND: A suboptimal response to the 2-dose COVID-19 vaccine series in the immunocompromised population prompted recommendations for a 3rd primary dose. We aimed to determine the humoral and cellular immune response to the 3rd COVID-19 vaccine in immunocompromised children. METHODS: Prospective cohort study of immunocompromised participants, 5–21 years old, who received 2 prior doses of an mRNA COVID-19 vaccine. Humoral and CD4/CD8 T-cell responses were measured to SARS-CoV-2 spike antigens prior to receiving the 3rd vaccine dose and 3–4 weeks after the 3rd dose was given. RESULTS: Of the 37 participants, approximately half were solid organ transplant recipients. The majority (86.5%) had a detectable humoral response after the 2nd and 3rd vaccine doses, with a significant increase in antibody levels after the 3rd dose. Positive T-cell responses increased from being present in 86.5% to 100% of the cohort after the 3rd dose. CONCLUSIONS: Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This supports the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in this population. IMPACT: Most immunocompromised children mount a humoral and cellular immune response to the 2-dose COVID-19 vaccine series, which is significantly augmented after receiving the 3rd vaccine dose. This is the first prospective cohort study to analyze both the humoral and T-cell immune response to the 3rd COVID-19 primary vaccine dose in children who are immunocompromised. The results of this study support the utility of the 3rd vaccine dose and the rationale for ongoing emphasis for vaccination against COVID-19 in the immunosuppressed pediatric population. Nature Publishing Group US 2022-11-14 /pmc/articles/PMC9662120/ /pubmed/36376507 http://dx.doi.org/10.1038/s41390-022-02374-4 Text en © The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Clinical Research Article
Morgans, Heather A.
Bradley, Todd
Flebbe-Rehwaldt, Linda
Selvarangan, Rangaraj
Bagherian, Amber
Barnes, Aliessa P.
Bass, Julie
Cooper, Ashley M.
Fischer, Ryan
Kleiboeker, Steve
Lee, Brian R.
LeMaster, Cas
Markus, Kelsey
Morrison, Stephen
Myers, Angela
Myers, Doug
Payne, Erin
Schuster, Jennifer E.
Standley, Sarah
Wieser, Andrea
Warady, Bradley
Humoral and cellular response to the COVID-19 vaccine in immunocompromised children
title Humoral and cellular response to the COVID-19 vaccine in immunocompromised children
title_full Humoral and cellular response to the COVID-19 vaccine in immunocompromised children
title_fullStr Humoral and cellular response to the COVID-19 vaccine in immunocompromised children
title_full_unstemmed Humoral and cellular response to the COVID-19 vaccine in immunocompromised children
title_short Humoral and cellular response to the COVID-19 vaccine in immunocompromised children
title_sort humoral and cellular response to the covid-19 vaccine in immunocompromised children
topic Clinical Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662120/
https://www.ncbi.nlm.nih.gov/pubmed/36376507
http://dx.doi.org/10.1038/s41390-022-02374-4
work_keys_str_mv AT morgansheathera humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT bradleytodd humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT flebberehwaldtlinda humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT selvaranganrangaraj humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT bagherianamber humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT barnesaliessap humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT bassjulie humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT cooperashleym humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT fischerryan humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT kleiboekersteve humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT leebrianr humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT lemastercas humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT markuskelsey humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT morrisonstephen humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT myersangela humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT myersdoug humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT payneerin humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT schusterjennifere humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT standleysarah humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT wieserandrea humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren
AT waradybradley humoralandcellularresponsetothecovid19vaccineinimmunocompromisedchildren